Treatment for Epstein-Barr virus-associated post-transplant lymphoproliferative disease

Herpes

Volumn 15, Issue 3, 2009, Pages 64-67

  Gross, Thomas G ^a,b  

^a NATIONWIDE CHILDREN S HOSPITAL   (United States)

^b THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Epstein barr virus; Post transplant lymphoproliferative disease; Therapy; Transplant recipients

Indexed keywords

ANTIINFECTIVE AGENT; ANTIVIRUS AGENT; AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN; GANCICLOVIR; HLA ANTIGEN; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN DERIVATIVE; RITUXIMAB; TACROLIMUS;

CELL PROLIFERATION; CELLULAR IMMUNITY; DISEASE ASSOCIATION; DONOR SELECTION; DRUG EFFICACY; DRUG INDICATION; DRUG TREATMENT FAILURE; EPSTEIN BARR VIRUS; GRAFT REJECTION; HEALTH CARE COST; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH RISK PATIENT; HUMAN; IMMUNE DEFICIENCY; IMMUNOPATHOGENESIS; IMMUNOSUPPRESSIVE TREATMENT; LOW DRUG DOSE; LYMPHOPROLIFERATIVE DISEASE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; UNSPECIFIED SIDE EFFECT; VIRUS INFECTION; VIRUS REPLICATION;

EPSTEIN-BARR VIRUS INFECTIONS; HERPESVIRUS 4, HUMAN; HUMANS; LYMPHOPROLIFERATIVE DISORDERS; ORGAN TRANSPLANTATION; POSTOPERATIVE COMPLICATIONS; RISK FACTORS;

HUMAN HERPESVIRUS 4;

EID: 63249088217     PISSN: 09697667     EISSN: 14701537     Source Type: Journal    
DOI: None     Document Type: Review

References (29)

1. Penn I, Hammond W, Brettschneider L, Starzl TE. Malignant lymphomas in transplantation patients. Transplant Proc 1969;1:106-112.
2. + T-cell frequencies by flow cytometry. Blood 1999;94:3094-3100.
3. Tan LC, Gudgeon N, Annels NE et al. A re-evaluation of the frequency of CD8+ T cells specific for EBV in healthy carriers. J Immunol 1999;162:1827-1835.
4. + responses to Epstein-Barr virus antigens. Blood 2000; 95:241-248.
5. Yang J, Tao Q, Flinn IW et al. Characterization of Epstein-Barr virus-infected B cells in patients with posttransplantation lymphoproliferative disease: disappearance after rituximab therapy does not predict clinical response. Blood 2000;96:4055-4063.
6. Gratama JW, Oosterveer MA, Zwaan FE et al. Eradication of Epstein-Barr virus by allogeneic bone marrow transplantation: implication for sites of viral latency. Proc Natl Acad Sci U S A 1988;85:8693-8696.
7. Gross TG, Steinbuch M, DeFor T et al. B cell lymphoproliferative disorder following hematopoietic stem cell transplantation: Risk factors, treatment and outcome. Bone Marrow Transplant 1999; 23:251-258.
8. Harris NL, Ferry JA, Swerdlow SH. Posttransplant lymphoproliferative disorders: summary of Society for Hematopathology Workshop. Semin Diagn Pathol 1997;14:8-14.
9. Curtis RE, Travis LB, Rowlings PA et al. Risk of lymphoproliferative disorders after bone marrow transplantation: a multiinstitutional study. Blood 1999;94:2208-2216.
10. Marshall NA, Howe JG, Formica R et al. Rapid reconstitution of Epstein-Barr virus-specific T lymphocytes following allogeneic stem cell transplantation. Blood 2000;96:2814-2821.
11. Opelz G, Döhler B. Lymphomas after solid organ transplantation: a collaborative transplant study report. Am J Transplant 2004; 4:222-230.
12. Buell, J., Gross TG, Woodle ES. Malignancy after transplantation. Transplantation 2005;80:S254-S264.
13. Gross TG, Hinrichs SH, Davis JR et al. Effect of counterflow elutriation (CE) on Epstein-Barr virus (EBV) infected cells in donor bone marrow. Exp Hematol 1998;26:395-399.
14. Paya CV, Nalesnik MA, Kieff E et al. Epstein-Barr virus-induced posttransplant lymphoproliferative disorders. Transplantation 1999;68:1517-1525.
15. Gross TG, Bucuvalas J, Park J et al. Low dose chemotherapy for the treatment of refractory post-transplant lymphoproliferative disease in children. J Clin Oncol 2005;23:6481-6488.
16. Green M, Michaels MG, Webber SA et al. The management of Epstein-Barr virus associated posttransplant lymphoproliferative disorders in pediatric solid-organ transplant recipients. Pediatr Transpl 1999;3:271-281.
17. Lucas KG, Burton RL, Zimmerman SE et al. Semiquantitative Epstein-Barr virus (EBV) polymerase chain reaction for determination of patients at risk for EBV-induced lymphoproliferative disease after stem cell transplantation. Blood 1998;91:3654-3661.
18. Rooney CM, Smith CA, Ng CY et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood 1998; 92:1549-1555.
19. Rowe DT, Webber S, Schauer EM et al. Epstein-Barr virus load monitoring: its role in the prevention and management of posttransplant lymphoproliferative disease. Transplant Infect Dis 2001; 3:79-87.
20. van Esser JWJ, van der Holt B, Meijer E et al. Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell-depleted SCT. Blood 2001;98:972-978.
21. + T lymphocytes after partially T-depleted allogeneic stem cell transplantation may identify patients at very high risk for progressive EBV reactivation and lymphoproliferative disease. Blood 2003;101:4290-4297.
22. Smets F Bazin H, Reding R et al. Ratio bewteen Epstein-Barr viral load and anti-Epstein-Barr virus specific T-cell response as a predictive marker of posttransplant lymphoproliferative disease. Transplantation 2002;73:1603-1610.
23. Lee TC, Goss JA, Rooney CM et al. Quantification of a low cellular immune response to aid in identification of pediatric liver transplant recipients at high-risk for EBV infection. Clin Transplant 2006; 20:689-694.
24. Hayashi RJ, Kraus MD, Patel AL et al. Posttransplant lymphoproliferative disease in children: correlation of histology to clinical behavior. J Pediatr Hematol Oncol 2001;23:14-18.
25. Aull MJ, Buell JF, Trofe J et al. Experience with 274 cardiac transplant recipients with posttransplant lymphoproliferative disorder: a report from the Israel Penn International Transplant Tumor Registry. Transplantation 2004;78:1676-1682.
26. Leblond V, Dhedin N, Mamzer Bruneel MF et al. Identification of prognostic factors in 61 patients with posttransplantation lymphoproliferative disorders. J Clin Oncol 2001; 19:772-778.
27. Trofe J, Buell JF, Beebe TM et al. Analysis of factors that influence survival with post-transplant lymphoproliferative disorder in renal transplant recipients: the Israel Penn International Transplant Tumor Registry experience. Am J Transplant 2005;5:775-780.
28. Perrine SP, Hermine O, Small T et al. A phase 1/2 trial of arginine butyrate and ganciclovir on patients with Epstein-Barr virus-associated lymphoid malignancies. Blood 2007; 109:2571-2578.
29. Papadopoulos EB, Ladanyi M, Emanuel D et al. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic